There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rigel (RIGL – Research Report) and ImmunoPrecise Antibodies (IPA – Research Report) with bullish sentiments.
Rigel (RIGL)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel, with a price target of $15.00. The company’s shares closed last Thursday at $1.22.
According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Rigel is a Strong Buy with an average price target of $5.25.
See the top stocks recommended by analysts >>
ImmunoPrecise Antibodies (IPA)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on ImmunoPrecise Antibodies today and set a price target of $9.00. The company’s shares closed last Thursday at $5.45.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on ImmunoPrecise Antibodies is a Moderate Buy with an average price target of $9.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RIGL:
- Rigel Pharmaceuticals doses first patient in Phase 1b study of R289
- Optime Care announces enhanced partnership with Rigel Pharmaceuticals
- Biotech Alert: Searches spiking for these stocks today
- Citi upgrades Rigel to Buy after leukemia approval comes earlier
- Rigel Pharmaceuticals upgraded to Buy from Neutral at Citi
